Search

Your search keyword '"Nadal, E."' showing total 1,072 results

Search Constraints

Start Over You searched for: Author "Nadal, E." Remove constraint Author: "Nadal, E." Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals
1,072 results on '"Nadal, E."'

Search Results

3. Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre

11. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

15. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

16. EE71 Cost-Effectiveness Analysis of Using Foundationone Liquid CDx in Patients With Advanced Non-Small Cell Lung Cancer in Whom Tissue-Based Testing Is Not Feasible

17. 115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC

18. P1.01-01 Frequency of Germline Mutations in Patients with Non-small Cell Lung Cancer (NSCLC) Harboring Actionable DRIVER Alterations (G-DRIVER)

19. EP08.03-01 Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials

20. P1.27-07 BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy

22. Locally equilibrated stress recovery for goal oriented error estimation in the extended finite element method

25. Mesh adaptivity driven by goal-oriented locally equilibrated superconvergent patch recovery

38. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.

41. 2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592

47. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients-correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project (Oct, 10.1038/s41379-022-01170-z, 2022)

50. P16.01.A Factors predicting cognitive impairment after intrathecal methotrexate treatment in patients with non-small cell lung cancer and leptomeningeal disease

Catalog

Books, media, physical & digital resources